Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2025)

Vivos Therapeutics' Return on Capital Employed history spans 5 years, with the latest figure at 2.72% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 2.72% for Q4 2025, down 164.0% from a year ago — trailing twelve months through Dec 2025 was 2.72% (down 164.0% YoY), and the annual figure for FY2025 was 9.29%, down 790.0%.
  • Return on Capital Employed for Q4 2025 was 2.72% at Vivos Therapeutics, down from 0.89% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.14% in Q4 2021 to a low of 5.35% in Q4 2023.
  • The 5-year median for Return on Capital Employed is 1.18% (2024), against an average of 1.85%.
  • The sharpest move saw Return on Capital Employed plummeted -328bps in 2023, then soared 427bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.14% in 2021, then tumbled by -1800bps to 2.71% in 2022, then crashed by -97bps to 5.35% in 2023, then skyrocketed by 80bps to 1.08% in 2024, then tumbled by -151bps to 2.72% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 2.72%, 0.89%, and 1.16% for Q4 2025, Q3 2025, and Q2 2025 respectively.